RAY121
/ Roche
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
November 09, 2025
Long lasting complement neutralisation by RAY121, an engineered anti-C1s antibody with C1q displacement function.
(PubMed, EBioMedicine)
- "RAY121 is able to neutralise the CP for an extended duration and is effective at doses that can be administered subcutaneously for convenient treatment. These data present RAY121 as a promising agent for the treatment of CP-driven autoimmune disorders."
Journal • Immunology
December 09, 2024
Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
(clinicaltrials.gov)
- P1 | N=144 | Enrolling by invitation | Sponsor: Chugai Pharmaceutical
New P1 trial • Pan tumor • Bullous Pemphigoid • Dermatology • Dermatomyositis • Dermatopathology • Genetic Disorders • Hematological Disorders • Immune Thrombocytopenic Purpura • Immunology • Myositis • Rare Diseases • Thrombocytopenia • Thrombocytopenic Purpura
September 25, 2024
RAY121, a Novel Recycling Monoclonal Antibody Against Complement C1s: Safety, Pharmacokinetic and Pharmacodynamic Data from a Phase 1a First in Human Clinical Trial in Healthy Adults
(ACR Convergence 2024)
- "In summary, the FIH study of RAY121 demonstrated that the application of Recycling Antibody engineering has been indeed translated into the substantial extension of the half-life of serum drug concentrations and the prolonged efficient suppression of CP with the favorable safety and PK profile. As a result, it has been hypothesized that infrequent SC dose of RAY121 enables maintaining complete suppression of classical complement pathway. The characteristic of monthly SC injection of RAY121 has a significant clinical value and is expected to be a new therapy, in reducing clinical burden on patients with autoimmune diseases."
Clinical • P1 data • PK/PD data • Immunology • C1S
July 08, 2024
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
(clinicaltrials.gov)
- P1 | N=144 | Recruiting | Sponsor: Chugai Pharmaceutical | Not yet recruiting ➔ Recruiting
Enrollment open • Pan tumor • Bullous Pemphigoid • Dermatology • Dermatomyositis • Dermatopathology • Genetic Disorders • Hematological Disorders • Immunology • Myositis • Rare Diseases • Thrombocytopenia • Thrombocytopenic Purpura
April 17, 2024
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
(clinicaltrials.gov)
- P1 | N=144 | Not yet recruiting | Sponsor: Chugai Pharmaceutical
New P1 trial • Pan tumor • Bullous Pemphigoid • Dermatology • Dermatomyositis • Dermatopathology • Genetic Disorders • Hematological Disorders • Immunology • Myositis • Rare Diseases • Thrombocytopenia • Thrombocytopenic Purpura
1 to 5
Of
5
Go to page
1